ARTIST 2: Implications for Treatment of Node-Positive Gastric Cancer

A new trial compares two adjuvant chemotherapy regimens and the addition of radiotherapy.

Standard therapy for resectable gastric cancer in the West is perioperative chemotherapy; in Asia, the most common practice is surgery with D2 gastrectomy followed by 6 months to 1 year of adjuvant chemotherapy. Recent trials have failed to demonstrate a survival advantage for postoperative radiation therapy, although the ARTIST trial reported a potential benefit for adding radiation to adjuvant chemotherapy in intestinal or node-positive gastric cancer (NEJM JW Oncol Hematol Mar 2015 and J Clin Oncol 2015; 33:3130).

Investigators from Korea now report the results of the ARTIST 2 trial, in which 546 patients with node-positive gastric cancer after D2 gastrectomy were randomized to one of three regimens: 1 year of adjuvant therapy with S-1, 6…

Reviewing Author

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

ARTIST 2: Implications for Treatment of Node-Positive Gastric Cancer

Topics

Reviewing Author